Journal: Antimicrobial Agents and Chemotherapy

Article Title: Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis ▿

doi: 10.1128/AAC.00548-10

Figure Lengend Snippet: Assay characteristics a

Article Snippet: Tazobactam sodium was obtained from LKT Laboratories, Inc. (St. Paul, MN; T0299).

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis ▿

doi: 10.1128/AAC.00548-10

Figure Lengend Snippet: Tazobactam concentration (μg/ml): dialysate effluent versus plasma free concentration, all data points; r2 = 0.92.

Article Snippet: Tazobactam sodium was obtained from LKT Laboratories, Inc. (St. Paul, MN; T0299).

Techniques: Concentration Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis ▿

doi: 10.1128/AAC.00548-10

Figure Lengend Snippet: Tazobactam concentration (μg/ml): dialysate effluent versus plasma free concentration, troughs only.

Article Snippet: Tazobactam sodium was obtained from LKT Laboratories, Inc. (St. Paul, MN; T0299).

Techniques: Concentration Assay

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Article Title: A Novel Framework to Compare the Effectiveness of β-lactamase Inhibitors against Extended-Spectrum β-lactamase-producing Enterobacteriaceae

doi: 10.1016/j.cmi.2019.01.003

Figure Lengend Snippet: Simulated piperacillin and β-lactamase inhibitor exposures

Article Snippet: Tazobactam was purchased from Chem-Impex International (Wood Dale, IL).

Techniques:

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Article Title: A Novel Framework to Compare the Effectiveness of β-lactamase Inhibitors against Extended-Spectrum β-lactamase-producing Enterobacteriaceae

doi: 10.1016/j.cmi.2019.01.003

Figure Lengend Snippet: Estimated E max model parameters, % f T> MIC i and predicted outcomes for tazobactam, relebactam and avibactam

Article Snippet: Tazobactam was purchased from Chem-Impex International (Wood Dale, IL).

Techniques: Bacteria

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Article Title: A Novel Framework to Compare the Effectiveness of β-lactamase Inhibitors against Extended-Spectrum β-lactamase-producing Enterobacteriaceae

doi: 10.1016/j.cmi.2019.01.003

Figure Lengend Snippet: Killing profiles for piperacillin in combination with tazobactam and avibactam against KpK91(a) and Kp2301 (b).

Article Snippet: Tazobactam was purchased from Chem-Impex International (Wood Dale, IL).

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

doi: 10.1186/s40360-024-00746-6

Figure Lengend Snippet: Names of concomitant drugs, drug classes, and sources of purchase

Article Snippet: Tazobactam , Antibiotic , Selleck Chemicals LLC.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

doi: 10.1128/aac.00775-24

Figure Lengend Snippet: MICs of β-lactams for AmpC-producing E. coli TOP10 recombinant strains ^a

Article Snippet: All others inhibitors (TAZ HY-W009168, AVI HY-14879, REL HY-16752, VAB HY-19930, NAC HY-109008, ZID HY-120859, TAN HY-109124, XER HY-136072, DUR HY-117974, EMT HY-103095) were purchased from MedChem Express (Luzern, Switzerland).

Techniques: Recombinant, Produced

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

doi: 10.1128/aac.00775-24

Figure Lengend Snippet: Determination of the 50% inhibitory concentration (IC 50 ) for β-lactamase inhibitors against AmpC enzymes ^a

Article Snippet: All others inhibitors (TAZ HY-W009168, AVI HY-14879, REL HY-16752, VAB HY-19930, NAC HY-109008, ZID HY-120859, TAN HY-109124, XER HY-136072, DUR HY-117974, EMT HY-103095) were purchased from MedChem Express (Luzern, Switzerland).

Techniques: Concentration Assay

Journal: International journal of pharmaceutics

Article Title: Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates.

doi: 10.1016/j.ijpharm.2022.122220

Figure Lengend Snippet: Fig. 3. Photos of the standard infusion set in the absence of simulated fluid volume support. A: Before the piperacillin/tazobactam infusion, B: After the start of the piperacillin/tazobactam infusion, C: A few minutes after the start of the piperacillin/tazobactam infusion, D: A few minutes before the end of the piperacillin/ tazobactam infusion, E: Several minutes after the end of the piperacillin/tazobactam infusion, and F: a few minutes after the end of the 9-hour infusion.

Article Snippet: Vancomycin hydrochloride (European Pharmacopeia (EP) chemical reference standard, 100 g, 01U772), tazobactam sodium (sc-205853A, 500 mg, Santa Cruz Biotechnology, Dallas, TX, USA) and piperacillin sodium (4 g, Panpharma, Luitré, France) were weighed carefully and diluted with ultrapure water (18.2 megaohms) by Purelab® classic water system (ELGA LabWater Antony, France) to obtain stock solutions and then calibration standards.

Techniques:

Journal: International journal of pharmaceutics

Article Title: Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates.

doi: 10.1016/j.ijpharm.2022.122220

Figure Lengend Snippet: Fig. 5. The change over time in the mass flow rate (MFR) for vancomycin as a percentage of the clinical target value in the “drug incompatibility” and control conditions, according to the plug-flow theory. The control curve corresponds to the drug level in the control infusion line, in which the piperacillin/tazobactam solution was replaced by SS. The “drug incompatibility” curve represents the infusion line combining both vancomycin and piperacillin/tazobactam syringes. The “plug-flow” line shows the theoretical results for the plug-flow model (Lovich et al., 2005). Lastly, the “target” value (100%) represents the DM flow rate requested by the clinicians. a: the standard infusion set in the absence of simulated fluid volume support, b: the standard infusion set with 10 mL/h simulated fluid volume support, c: the standard infusion set with 20 mL/h simulated fluid volume support, d: the three-lumen infusion set in the absence of simulated fluid volume support, e: the three-lumen infusion set with 10 mL/h simulated fluid volume support, f: the three-lumen infusion set with 20 mL/h simulated fluid volume support. (mean, n = 3)..

Article Snippet: Vancomycin hydrochloride (European Pharmacopeia (EP) chemical reference standard, 100 g, 01U772), tazobactam sodium (sc-205853A, 500 mg, Santa Cruz Biotechnology, Dallas, TX, USA) and piperacillin sodium (4 g, Panpharma, Luitré, France) were weighed carefully and diluted with ultrapure water (18.2 megaohms) by Purelab® classic water system (ELGA LabWater Antony, France) to obtain stock solutions and then calibration standards.

Techniques: Control

Journal: International journal of pharmaceutics

Article Title: Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates.

doi: 10.1016/j.ijpharm.2022.122220

Figure Lengend Snippet: Fig. 6. The change over time in the mass flow rate (MFR) for piperacillin and tazobactam as a percentage of the theoretical value in the plug-flow model. The “drug incompatibility” curve represents the infusion line combining both vancomycin and piperacillin/tazobactam syringes. The “plug-flow” line shows the theoretical results for the plug-flow model (Lovich et al., 2005). Lastly, the “target” value (100%) represents the DM flow rate requested by the clinicians (mean, n = 3). a: the standard infusion set in the absence of simulated fluid volume support, b: the standard infusion set with 10 mL/h simulated fluid volume support, c: the standard infusion set with 20 mL/h simulated fluid volume support, d:.three-lumen infusion set in the absence of simulated fluid volume support, e: the three-lumen infusion set with 10 mL/h simulated fluid volume support, f: the three-lumen infusion set with 20 mL/h simulated fluid volume support, (mean ± SD, n = 3).

Article Snippet: Vancomycin hydrochloride (European Pharmacopeia (EP) chemical reference standard, 100 g, 01U772), tazobactam sodium (sc-205853A, 500 mg, Santa Cruz Biotechnology, Dallas, TX, USA) and piperacillin sodium (4 g, Panpharma, Luitré, France) were weighed carefully and diluted with ultrapure water (18.2 megaohms) by Purelab® classic water system (ELGA LabWater Antony, France) to obtain stock solutions and then calibration standards.

Techniques: